Russia Launches Innovative Brain Tumor Detection Drug in Siberia

Production of an innovative radiopharmaceutical designed for the early detection of brain tumors has begun at the Nuclear Medicine Center in Ulan-Ude, according to the Far East and Arctic Development Corporation (FEDC). The new radiotracer, 18F-FET (fluoroethyltyrosine), is used in PET/CT imaging and is considered one of the most effective tools for identifying brain tumors at an early stage. Until now, patients seeking examinations with this radiopharmaceutical had to travel to medical centers in central Russia. With local production now underway, the service has become available in the Russian Far East and is provided free of charge under the country's compulsory health insurance program.